Related Experiment Videos
Update on cyclophosphamide for systemic lupus erythematosus
1Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA. Robert_Ortmann@nih.gov
Rheumatic Diseases Clinics of North America
|April 18, 2000
Summary
Cyclophosphamide is a key treatment for severe systemic lupus erythematosus (SLE), especially lupus nephritis. This review covers its use in lupus nephritis, vasculitis, and CNS disease, plus potential side effects.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Cyclophosphamide has become a vital therapy for severe systemic lupus erythematosus (SLE) over the last decade.
- Its use is particularly established in managing life-threatening SLE manifestations.
Purpose of the Study:
- To review the current applications of cyclophosphamide in managing lupus nephritis.
- To expand on the role of cyclophosphamide in other severe SLE manifestations.
- To discuss the potential complications associated with cyclophosphamide therapy.
Main Methods:
- Literature review of clinical studies and therapeutic guidelines.
- Analysis of treatment protocols for cyclophosphamide in SLE management.
- Synthesis of data on efficacy and adverse events.
Main Results:
- Intravenous pulse cyclophosphamide is the standard for diffuse proliferative lupus nephritis (WHO Class IV).
- Evidence supports cyclophosphamide use in lupus vasculitis and acute CNS lupus.
- The review consolidates information on cyclophosphamide's benefits and risks.
Conclusions:
- Cyclophosphamide is a cornerstone in treating severe SLE, including lupus nephritis and other organ-specific conditions.
- Understanding its efficacy and potential complications is crucial for optimal patient management.
- Further research may refine its role and safety profile in SLE treatment.